Efficacy and Safety of Vildagliptin as an Add-on to Insulin with or without Metformin in Japanese Patients with Type 2 Diabetes Mellitus: A 12-week, Double-Blind, Randomized Study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1869-6961
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Efficacy and Safety of Vildagliptin as an Add-on to Insulin with or without Metformin in Japanese Patients with Type 2 Diabetes Mellitus: A 12-week, Double-Blind, Randomized Study ; volume:6 ; number:4 ; day:30 ; month:11 ; year:2015 ; pages:559-571 ; date:12.2015
Diabetes therapy ; 6, Heft 4 (30.11.2015), 559-571, 12.2015
- Creator
-
Hirose, Takahisa
Suzuki, Manabu
Tsumiyama, Isao
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s13300-015-0147-6
- URN
-
urn:nbn:de:101:1-2019080819352617875491
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:34 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Hirose, Takahisa
- Suzuki, Manabu
- Tsumiyama, Isao
- SpringerLink (Online service)
Other Objects (12)
Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial
Metformin add-on continuous subcutaneous insulin infusion on precise insulin doses in patients with type 2 diabetes
Empagliflozin versus Sitagliptin as add-on dual therapy in Egyptian patients with type 2 diabetes inadequately controlled with Metformin: a 12-week randomized, open-label, parallel-group trial
Efficacy and Safety of Vildagliptin as Add-on to Metformin in Japanese Patients with Type 2 Diabetes Mellitus
Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study
Correction: Empagliflozin versus Sitagliptin as add-on dual therapy in Egyptian patients with type 2 diabetes inadequately controlled with Metformin: a 12-week randomized, open-label, parallel-group trial
PPAR agonists as add-on treatment with metformin in management of type 2 diabetes: a systematic review and meta-analysis
Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
Market Regulation of Voluntary Add-on Contracts
Shrouding add-on information: an experimental study
The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-on Therapy to Metformin in Patients with Uncontrolled Type 2 Diabetes Mellitus
Therapeutic Effects of Add-On Tenapanor for Hemodialysis Patients with Refractory Hyperphosphatemia
Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial
Metformin add-on continuous subcutaneous insulin infusion on precise insulin doses in patients with type 2 diabetes
Empagliflozin versus Sitagliptin as add-on dual therapy in Egyptian patients with type 2 diabetes inadequately controlled with Metformin: a 12-week randomized, open-label, parallel-group trial
Efficacy and Safety of Vildagliptin as Add-on to Metformin in Japanese Patients with Type 2 Diabetes Mellitus
Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study
Correction: Empagliflozin versus Sitagliptin as add-on dual therapy in Egyptian patients with type 2 diabetes inadequately controlled with Metformin: a 12-week randomized, open-label, parallel-group trial
PPAR agonists as add-on treatment with metformin in management of type 2 diabetes: a systematic review and meta-analysis
Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
Market Regulation of Voluntary Add-on Contracts
Shrouding add-on information: an experimental study
The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-on Therapy to Metformin in Patients with Uncontrolled Type 2 Diabetes Mellitus
Therapeutic Effects of Add-On Tenapanor for Hemodialysis Patients with Refractory Hyperphosphatemia
Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial
Metformin add-on continuous subcutaneous insulin infusion on precise insulin doses in patients with type 2 diabetes
Empagliflozin versus Sitagliptin as add-on dual therapy in Egyptian patients with type 2 diabetes inadequately controlled with Metformin: a 12-week randomized, open-label, parallel-group trial
Efficacy and Safety of Vildagliptin as Add-on to Metformin in Japanese Patients with Type 2 Diabetes Mellitus
Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study
Correction: Empagliflozin versus Sitagliptin as add-on dual therapy in Egyptian patients with type 2 diabetes inadequately controlled with Metformin: a 12-week randomized, open-label, parallel-group trial
PPAR agonists as add-on treatment with metformin in management of type 2 diabetes: a systematic review and meta-analysis
Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
Market Regulation of Voluntary Add-on Contracts
Shrouding add-on information: an experimental study
The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-on Therapy to Metformin in Patients with Uncontrolled Type 2 Diabetes Mellitus